Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $40,832.52 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 35,818 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $1.14, for a total transaction of $40,832.52. Following the sale, the director directly owned 3,676,534 shares of the company’s stock, valued at $4,191,248.76. This represents a 0.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $28,450.09.
• On Monday, November 10th, Luke Evnin sold 31,172 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total transaction of $36,782.96.
• On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $48,784.50.
• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $42,285.87.
• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $37,544.28.
• On Tuesday, November 4th, Luke Evnin sold 90,164 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $110,000.08.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $77,876.01.
• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $93,685.76.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total value of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $133,538.70.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.92 on Friday. The business has a fifty day simple moving average of $1.57 and a 200 day simple moving average of $1.33. The company has a market cap of $44.57 million, a P/E ratio of -0.57 and a beta of 0.72. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. On average, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HOWL. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. JMP Securities decreased their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Bank of America lowered their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 25th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its stake in shares of Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares during the last quarter. MPM Asset Management LLC grew its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the last quarter. MPM Bioimpact LLC increased its holdings in Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Nuveen LLC bought a new position in Werewolf Therapeutics during the 1st quarter worth $71,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Werewolf Therapeutics during the 2nd quarter worth $92,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.